SIMCERE PHARMA(02096): SIM0686(FGFR2b monoclonal antibody-drug conjugate) has obtained the drug clinical trial approval notification issued by the National Medical Products Administration.

SIMCERE PHARMA (02096) announced that on April 9, 2025, the group's independently developed anti-tumor candidate drug FGFR2b antibody-drug conjugate (ADC) SIM0686 has obtained the drug clinical trial approval notification issued by the China National Medical Products Administration, and plans to conduct clinical trials for advanced solid tumors. SIM0686 is a targeted ADC drug against FGFR2b. Fibroblast growth factor receptor (FGFR) is a transmembrane tyrosine kinase receptor for fibroblast growth factor (FGF), with four known subtypes including FGFR1, FGFR2, FGFR3, and FGFR4. This ADC is intended to be developed for the treatment of advanced malignant tumors such as gastric cancer and lung cancer.